Our customers' Feedback
Search:
Perform search
Categories list

Generic Symbicort

News
Symbicort
Symbicort photo

Generic Symbicort (Budesonide Formoterol)

Anti-inflammatories, Asthma

PackagePricePer ItemSavingsOrder
100mcg + 6mcg 120 dpi × 1 inhaler$34.95$34.95Add to cart
100mcg + 6mcg 120 dpi × 2 inhaler$59.95$29.98$9.95Add to cart

PackagePricePer ItemSavingsOrder
160mcg + 4.5mcg 60 dpi × 1 inhaler$69.95$69.95Add to cart
160mcg + 4.5mcg 60 dpi × 2 inhaler$129.95$64.97-Add to cart

PackagePricePer ItemSavingsOrder
200mcg + 6mcg 120 dpi × 1 inhaler$39.95$39.95Add to cart
200mcg + 6mcg 120 dpi × 2 inhaler$69.95$34.98$9.95Add to cart

PackagePricePer ItemSavingsOrder
400mcg + 6mcg 120 dpi × 1 inhaler$44.95$44.95Add to cart
400mcg + 6mcg 120 dpi × 2 inhaler$79.95$39.98$9.95Add to cart

Most popular quantity.
Temovate
$ 3.00
Generic Temovate
(Clobetasol 0.05% 15g)
Ventolin
$ 0.50
Generic Ventolin
(Albuterol (salbutamol) 2/4mg)
Ventolin Inhaler
$ 13.74
Generic Ventolin Inhaler
(Albuterol 100mcg 200dpi)
Volmax Cr
$ 0.51
Generic Volmax Cr
(Albuterol (salbutamol) 4/8mg)
Voltaren
$ 0.58
Generic Voltaren
(Diclofenac Sodium 50/100mg)
Xylocaine
$ 5.00
Generic Xylocaine
(Lidocaine 2% 30g)
Social bookmarks:
Articles
Choose your language:



Money backguarantee
Secureshopping

Our billing is certified by:

Secure shopping certificates

Special Offer!

  • Astellas Reports First Quarter Financial Results of FY2016 - Business Wire (press release)

    Astellas Reports First Quarter Financial Results of FY2016Business Wire (press release)This reflected underlying growth in sales of products including overall OAB treatments (Vesicare® and Betanis®), Celecox® (celecoxib) and Symbicort® (budesonide and formoterol fumarate dihydrate).

  • AstraZeneca (AZN) Tops Q2 EPS by 7c - StreetInsider.com

    AstraZeneca (AZN) Tops Q2 EPS by 7cStreetInsider.

  • Glaxo stokes triple-combo hopes with data topping AZ's Symbicort - FiercePharma

    FiercePharmaGlaxo stokes triple-combo hopes with data topping AZ's SymbicortFiercePharmaMonday, the company announced that the pipeline med had nailed both of its primary endpoints in a Phase III study, topping rival Symbicort from AstraZeneca on metrics measuring lung function and health-related quality of life.

  • Which Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings? - Market Realist

    Market RealistWhich Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings?Market RealistThe respiratory product sales are expected to increase operationally due to revenues from the blockbuster drugs Symbicort and Pulmicort, as well as new products including Tudorza, Daliresp, and Duaklir.

  • Finland calls on WADA to check Norwegian skiers with asthma for doping - RT

    RTFinland calls on WADA to check Norwegian skiers with asthma for dopingRTIn 2011, WADA legalized the anti-asthma drug symbicort, which was being used by famous Norwegian skier Marit Bjoergen at that time.

    Copyright © cheapgenerics24.com